Platform for efficient development of innovative anti-cancer therapies

Torqur is a Swiss clinical-stage biotech company launched in 2021 as a subsidiary of Swiss Rockets, a Basel-based incubator and accelerator of start-up companies in oncology and infectiology.

LEARN MORE
Our Mission

Fulfil patients' expectations through precise science.

Each cancer treatment remains a case-by-case battle, with a limited panel of therapeutic options available. Considering the relatively low response of cancer patients to standards of care that are effective only in a narrow subset of patients, there is a tremendous need for new targeted therapies.

LEARN MORE
What we do

Strategy

Research and development experts at Torqur aim to create a portfolio of disease-specific mTOR and/or PI3K inhibitors with optimized pharmacokinetic and safety properties. By employing the most promising molecules designed to specifically inhibit desired pathways of cancer cells and minimize possible drug toxicity, Torqur intends to turn cancer into a manageable disease.

LEARN MORE

TECHNOLOGY

The PI3K/Akt/mTOR pathway is one of the major cellular pathways that plays a key role in basic intracellular functions including cell growth, proliferation, motility, differentiation, and survival. Disruption and abnormal activation of the PI3K/Akt/mTOR pathway are frequently observed in various human malignancies making this pathway an attractive therapeutic target in the treatment of cancer.

LEARN MORE
BOARD OF DIRECTORS

Prof. Dr. Michael N. Hall

Chairman and Non-Executive Board Member

Prof. Dr. Michael N. Hall is an American and Swiss molecular biologist and Professor at the Biozentrum of the University of Basel. He earned a Ph.D. in Molecular Genetics from Harvard University in 1981 and was a postdoctoral fellow at the Institut Pasteur in Paris and the University of California, San Francisco.

READ MORE

Dr. Vladimir Cmiljanovic

Vice-Chairman and Executive Board Member

Dr. Vladimir Cmiljanovic is one of Switzerland's leading serial biotech entrepreneurs, a medicinal chemist, and a cancer scientist with more than fifteen years of experience in oncology drug development.

READ MORE

Dr. Thomas Ladner

Non-Executive Board Member Member & Secretary

Dr. Thomas Ladner, Board Member and Secretary of the Board, became in 2002 the youngest partner at Meyerlustenberger Lachenal, one of Switzerland's leading law firms, where he specialized in private equity and M&A. From 2000 to 2004, Thomas lectured on corporate law and contract law at the University of St. Gallen (Switzerland), from where he also holds a Ph.D.

READ MORE

Dr. Jeanette Wood

Non-Executive Board Member

Dr. Jeanette Wood is an accomplished scientist with extensive experience in all aspects of drug discovery across multiple disease areas, including cancer.

READ MORE

Dr. Natasa Cmiljanovic

Executive Board Member

Dr. Natasa Cmiljanovic, Chief Scientific Officer and Founder, is a medicinal chemist and clinical scientist with more than ten years of experience in oncology drug development. She is the co-author of various scientific articles and abstracts and inventor of numerous patents.

READ MORE

Christoph Tschumi

Non-Executive Board Member

Christoph Tschumi is a senior business consultant with a focus on organisational development, governance, as well as economic analysis and risk management. He is member of various boards. In the Foundation Board of the Basel Institute on Governance, as well as the board of Pension Fund of the Canton Basel-Stadt he is head of the finance and audit committees.

READ MORE